SEQ-9

• Description:

  SEQ-9 is an orally active Mycobacterium tuberculosis (Mtb) 23S bacterial ribosome inhibitor with an IC50 of approximately 170 nM for unmethylated Mtb ribosomes. SEQ-9 also potently inhibits A2296 methylated ribosomes. SEQ-9 can be used to study bacterial infection and drug resistance[1].

• UNSPSC:

  12352005

• Target:

  Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/seq-9.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C[C@H] ([C@@] ([C@@H]1C) ([H]) OC ([C@H] (C) [C@H] ([C@@H] ([C@H] ([C@@H] (C) C[C@@] (OC (NC (C) (C) CNS (C2=CC=CC=C2) (=O) =O) =O) (C) C ([C@@H] ([C@@H]1OC (CC (C) C) =O) C) =O) O[C@]3 ([H]) O[C@] ([H]) (C) C/C ([C@H]3O) =N/OC) C) O[C@]4 ([H]) O[C@@H] (C) CN (C) [C@H] (C) C4) =O) O[C@@]5 ([H]) [C@H] (OC) [C@H] (OC) [C@H] (O) [C@] (C) ([H]) O5

• Molecular Formula:

  C60H100N4O20S

• Molecular Weight:

  1229.52

• References & Citations:

  [1]ZHICHENG CUI. Structural Studies of Mycobacterium Tuberculosis Ribosome: From Translational Regulation to Drug Resistance. Texas A&M University. 2021 Apr 12.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported